This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PDGFRA · Western blot design guide
PDGFRA Western Blot Planning Guide
Plan a PDGFRA Western blot around the catalog-observed 122.7 kDa band, image-backed A00366 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
PDGFRA Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 122.7 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Appendix | |
| Negative control | Bronchus |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 122.7 kDa |
| ⓘ | Localization | Cell membrane / Cell projection, cilium |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated PDGFRA Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Appendix |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A00366 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected PDGFRA Western Blot Band Size?
Use the product-observed 122.7 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 122.7 kDa | Matches the authoritative product WB observation. |
| 122.7 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected PDGFRA appearancePlan around 122.7 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 122.7 kDa; use this as the primary experimental expectation. |
| Calculated mass | 122.7 kDa from UniProt P16234; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A00366. |
| Situation | Likely cause | Next action |
|---|---|---|
| 122.7 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing PDGFRA band
A00366 · PDGFRA
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for PDGFRA Western blot
🧪Use Appendix as the first positive-control candidate and Bronchus as the HPA Not detected negative candidate.
Positive control: Appendix (High)
Negative control: Bronchus (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for PDGFRA
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Reported tissue cells | High | Protein (HPA) | HPA → |
| Endometrium | Reported tissue cells | High | Protein (HPA) | HPA → |
| Rectum | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced PDGFRA Western Blot Tips
Deeper troubleshooting and optimisation questions for PDGFRA, answered from its protein features.
Which band should guide the blot?
Use 122.7 kDa, the observation attached to the authoritative A00366 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 122.7 kDa expectation.
Which positive control should I start with?
Start with Appendix, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bronchus as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for PDGFRA Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A00366 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
PDGFRA Western Blot Reagents
Human/Mouse/Rat-reactive PDGFRA Western blot reagents with authoritative product imagery.
Real WB data
Anti-PDGFRA Antibody Picoband®
Cat # A00366
Real WB data
Anti-PDGF Receptor alpha/PDGFRA Antibody Picoband®
Cat # PB9771
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P16234
- Human Protein Atlas — PDGFRA
- A00366 product record
- PMC10239357 — Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in PDGFRA D842V-Mutant Gastrointestinal Stromal Tumor (Clinical cancer research : an official journal of the American Association for Cancer Research, 2023)
- PMC12121847 — Effective targeting of PDGFRA-altered high-grade glioma with avapritinib (Cancer cell, 2025)